share_log

Walleye Capital LLC Purchases Shares of 7,926 Prestige Consumer Healthcare Inc. (NYSE:PBH)

Defense World ·  Sep 23, 2022 04:31

Walleye Capital LLC purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,926 shares of the company's stock, valued at approximately $420,000.

Several other institutional investors and hedge funds have also recently modified their holdings of PBH. The Manufacturers Life Insurance Company raised its holdings in shares of Prestige Consumer Healthcare by 5.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 665,367 shares of the company's stock valued at $35,225,000 after buying an additional 31,655 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Prestige Consumer Healthcare by 19.3% during the 1st quarter. Jane Street Group LLC now owns 8,155 shares of the company's stock valued at $432,000 after buying an additional 1,319 shares in the last quarter. Lido Advisors LLC purchased a new position in shares of Prestige Consumer Healthcare during the 1st quarter valued at about $341,000. Quantbot Technologies LP raised its holdings in shares of Prestige Consumer Healthcare by 2,284.1% during the 1st quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock valued at $190,000 after buying an additional 3,449 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Prestige Consumer Healthcare during the 1st quarter valued at about $971,000. Hedge funds and other institutional investors own 99.37% of the company's stock.

Get Prestige Consumer Healthcare alerts:

Prestige Consumer Healthcare Price Performance

PBH opened at $50.75 on Friday. The stock's 50 day simple moving average is $55.30 and its 200 day simple moving average is $55.45. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.09 and a quick ratio of 1.23. Prestige Consumer Healthcare Inc. has a 1 year low of $49.69 and a 1 year high of $63.83. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 1.51 and a beta of 0.55.

Analysts Set New Price Targets

Separately, DA Davidson reissued a "neutral" rating on shares of Prestige Consumer Healthcare in a report on Tuesday, August 9th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $80.50.

Prestige Consumer Healthcare Profile

(Get Rating)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

See Also

  • Get a free copy of the StockNews.com research report on Prestige Consumer Healthcare (PBH)
  • The Institutions Hold On To Darden Restaurants International
  • What Steelcase's Earnings Say About the Return to the Office?
  • Is The Golden Age Of Homebuilding Already Over?
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating).

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment